These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1051 related items for PubMed ID: 11061941

  • 1. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE.
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer.
    Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, Abbou CC, Chopin DK.
    J Urol; 2002 Jan; 167(1):364-7. PubMed ID: 11743357
    [Abstract] [Full Text] [Related]

  • 5. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y, Sawada Y, Inagaki T, Kohjimoto Y, Uekado Y, Shinka T.
    Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
    [Abstract] [Full Text] [Related]

  • 6. [Assessment of 8-hydroxy-2'-deoxyguanosine concentrations in bladder cancer patients treated with intravesical BCG instillation].
    Kaczmarek P, Błaszczyk J, Fijałkowski P, Sierakowska-Fijałek A, Niemirowicz J, Kasprzak A, Baj Z.
    Pol Merkur Lekarski; 2005 Oct; 19(112):526-8. PubMed ID: 16379317
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [Abstract] [Full Text] [Related]

  • 12. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG.
    Sanchez-Carbayo M, Urrutia M, Romani R, Herrero M, Gonzalez de Buitrago JM, Navajo JA.
    Anticancer Res; 2001 Apr; 21(4B):3041-7. PubMed ID: 11712808
    [Abstract] [Full Text] [Related]

  • 13. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
    Pansadoro V, Emiliozzi P, depaula F, Scarpone P, Pizzo M, Federico G, Martini M, Pansadoro A, Sternberg CN.
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
    [Abstract] [Full Text] [Related]

  • 14. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
    Demkow T, Alter A, Wiechno P.
    Urol Int; 2008 Dec; 80(1):74-9. PubMed ID: 18204238
    [Abstract] [Full Text] [Related]

  • 15. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome.
    Hausladen DA, Wheeler MA, Altieri DC, Colberg JW, Weiss RM.
    J Urol; 2003 Jul; 170(1):230-4. PubMed ID: 12796695
    [Abstract] [Full Text] [Related]

  • 16. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V, Pode D, Pikarsky E, Mandelboim O.
    J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
    [Abstract] [Full Text] [Related]

  • 17. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY, Shipley WU, Dahl DM, Coen JJ, Heney NM, Kaufman DS, Zietman AL.
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [Abstract] [Full Text] [Related]

  • 18. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
    Zlotta AR, Noel JC, Fayt I, Drowart A, Van Vooren JP, Huygen K, Simon J, Schulman CC.
    J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
    [Abstract] [Full Text] [Related]

  • 19. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy.
    Hurle R, Losa A, Ranieri A, Graziotti P, Lembo A.
    J Urol; 1996 Nov; 156(5):1602-5. PubMed ID: 8863547
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.